Pharmacophore an International Research Journal
Pharmacophore
Submit Manuscript
Open Access | Published: 2014 - Issue 4

FORMULATION AND OPTIMIZATION OF THERMOREVERSIBLE IN-SITU GEL OF VENLAFAXINE HCl Download PDF


Shete Prathmesh M and Shinde Ajay D
Abstract

The purpose of this research was to study the in-situ nasal gel system containing Venlafaxine HCl suitable for administration in nose was formulated by cold method using combination of Poloxamer 407 and Polyvinyl pyrrolidone (PVP). Thermoreversible, bioadhesive polymers such as Poloxamer 407 and PVP in the form of in situ gel by cold technique. To modulate the gel strength and bioadhesive force for Venlafaxine HCl nasal gel, bioadhesive polymers PVP were investigated. The gels were evaluated for gelation temperature, bioadhesive force, gel strength, viscosity, Drug content and in-vitro release. A 2-factor, 2-level full factorial design (22) was employed for optimization of Venlafaxine HCl gels with Poloxamer 407 amount (%, X1) and polymers (PVP %, X2) as the prime selected independent variables, which were varied at 2 different levels (low and high). The effect of formulation variables on the response variables were statistically evaluated by using a commercially available software package Design-Expert® version 8.0.1. The results revealed that as the increase of bioadhesive polymer PVP concentration, decrease in gelation temperature (T). pH of all formulation were found to be within the range between 6 to 6.5. The drug content for all formulation was found to be 96%-100%. The mucoadhesive test indicates that the level of PVP increases, the mucoadhesive strength also increases. The developed formulations had optimum viscosity. The optimized formulation shows the controlled drug release. This study further demonstrates that administration of Venlafaxine Hcl intranasal in gel form is a pleasant and painless alternative.

QR code:

Short Link:
Quick Access

Pharmacophore
ISSN: 2229-5402

Pharmacophore
© 2024 All rights reserved
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.